Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
May 8, 2026 - 02:27
Absci has provided updates on its clinical programs and released its financial results for the first quarter of 2026. The company announced it has successfully dosed all four planned healthy volunteer cohorts in the single ascending dose (SAD) portion of its ongoing ABS-201 HEADLINE trial. The drug, being developed for androgenetic alopecia (AGA), or pattern hair loss, was reported to be well-tolerated with favorable emerging safety data.
Preliminary pharmacokinetic modeling from the HEADLINE trial supports the targeted dosing interval for ABS-201. The company has also initiated dosing for the first multiple ascending dose (MAD) cohort in participants with AGA.
Beyond ABS-201, Absci is expanding its prolactin program by adding ABS-202 to its internal pipeline. The company is headquartered in Vancouver, Washington, and also has operations in New York. The first quarter financial report covers the period ending March 31, 2026.
MORE NEWS
June 21, 2026 - 22:47
Billionaire fires back at Mamdani, says business leaders must 'fight for their city'Billionaire hedge fund manager Ken Griffin fired back at New York Mayor Zohran Mamdani on Tuesday, arguing that business leaders have a responsibility to defend their city against what he called...
June 21, 2026 - 12:56
Afghan Women Turn to Business Under Taliban RestrictionsWith secondary schools and most formal jobs now closed to them, thousands of Afghan women have found entrepreneurship to be their only remaining route to earn money and stay connected with the...
June 20, 2026 - 23:07
Scammers using AI to make fake moving companies look more convincingSummer is peak moving season, and the Better Business Bureau is warning consumers that scammers are now using artificial intelligence to create highly convincing fake moving companies. These...
June 20, 2026 - 03:57
First US patient enrolled in device study to reduce coronary microvascular dysfunctionA new clinical study has begun in the United States, testing a device designed to treat coronary microvascular dysfunction, a condition that affects the heart`s smallest blood vessels. The first...